Evol Science is a startup biotechnology company focused on identifying and therapeutically exploiting mechanisms of cancer cell resistance, which we discover using our proteo-genomic system and proprietary data analytic software.
We have developed a novel drug combination with a potential to treat pancreatic cancer. We have created a second drug combination with the potential to treat acquired resistance metastatic melanoma. Our goal is to make the deadliest cancers survivable.
Newly Published Research:
AACR Journals - Molecular Cancer Therapeutics
Kayleigh C Ross, Andrew J. Andrews, Christopher D Marion, Timothy J. Yen and Vikram Bhattacharjee*
Published OnlineFirst May 12, 2017. DOI: 10.1158/1535-7163.MCT-16-0798
Metastatic melanoma cells commonly acquire resistance to BRAF V600E inhibitors (BRAFis). In this study, we identified serine biosynthesis as a critical mechanism of resistance. Proteomic assays revealed differential protein expression of serine biosynthetic enzymes PHGDH, PSPH, and PSAT1 following vemurafenib (BRAFi) treatment in sensitive versus acquired resistant melanoma cells. Ablation of PHGDH via siRNA sensitized acquired resistant cells to vemurafenib. Inhibiting the folate cycle, directly downstream of serine synthesis, with methotrexate also displayed similar sensitization. Using the DNA damaging drug gemcitabine, we show that gemcitabine pre-treatment sensitized resistant melanoma cells to BRAFi's vemurafenib and dabrafenib. We extended our findings to BRAF WT tumor cell lines that are intrinsically resistant to vemurafenib and dabrafenib. Pre-treatment of pancreatic cancer and non-small cell lung cancer cell lines with sublethal doses of 50nM and 5nM of gemcitabine respectively, enhanced killing by both vemurafenib and dabrafenib. The novel aspects of this study are the direct identification of serine biosynthesis as a critical mechanism of BRAF V600E inhibitor resistance and the first successful example of using gemcitabine + BRAFi's in combination to kill previously drug resistant cancer cells, creating the translational potential of pre-treatment with gemcitabine prior to BRAFi treatment of tumor cells to reverse resistance within the mutational profile and the WT.
* - Corresponding Author